Flurbiprofen@ZIF-8 nanoformulation with potential for analgesia

Area of Science:

• Materials Science
• Nanotechnology
• Pharmacology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) offer pain relief but cause gastrointestinal issues.
• Flurbiprofen, a potent NSAID, has therapeutic potential but non-selective cyclooxygenase (COX) inhibition limits its use.
• Developing targeted NSAID delivery systems can improve efficacy and reduce adverse effects.

Purpose of the Study:

• To create flurbiprofen-loaded ZIF-8 nanoparticles (FP@ZIF-8) for enhanced NSAID delivery.
• To evaluate the efficacy and safety of FP@ZIF-8 for treating inflammatory pain.

Main Methods:

• Synthesized flurbiprofen-loaded ZIF-8 nanoparticles.
• Assessed drug loading, pH-responsive release, and in vitro cell responses (HUVEC proliferation, ROS reduction).
• Conducted in vivo studies in mouse models for pain alleviation and cytokine downregulation, alongside biosafety assessments.

Main Results:

• FP@ZIF-8 achieved high flurbiprofen loading (up to 53%) with pH-responsive release.
• Nanoparticles promoted HUVEC proliferation and reduced LPS-induced ROS in macrophages.
• In vivo studies demonstrated effective pain relief and reduced inflammatory cytokines with excellent biocompatibility.

Conclusions:

• FP@ZIF-8 nanoparticles represent a promising drug delivery system for flurbiprofen.
• This system enhances therapeutic efficacy while mitigating NSAID-related side effects.
• FP@ZIF-8 shows significant potential for managing inflammatory pain conditions.